Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204


Living Neurons with Tau Filaments Aberrantly Expose Phosphatidylserine and Are Phagocytosed by Microglia.

Brelstaff J, Tolkovsky AM, Ghetti B, Goedert M, Spillantini MG.

Cell Rep. 2018 Aug 21;24(8):1939-1948.e4. doi: 10.1016/j.celrep.2018.07.072.


Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells.

Whiten DR, Zuo Y, Calo L, Choi ML, De S, Flagmeier P, Wirthensohn DC, Kundel F, Ranasinghe RT, Sanchez SE, Athauda D, Lee SF, Dobson CM, Gandhi S, Spillantini MG, Klenerman D, Horrocks MH.

Chembiochem. 2018 Jul 27. doi: 10.1002/cbic.201800209. [Epub ahead of print]


Influence of Drug-Carrier Polymers on Alpha-Synucleinopathies: A Neglected Aspect in New Therapies Development.

Tonda-Turo C, Herva M, Chiono V, Ciardelli G, Spillantini MG.

Biomed Res Int. 2018 Feb 21;2018:4518060. doi: 10.1155/2018/4518060. eCollection 2018.


Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies.

Forrest SL, Kril JJ, Stevens CH, Kwok JB, Hallupp M, Kim WS, Huang Y, McGinley CV, Werka H, Kiernan MC, Götz J, Spillantini MG, Hodges JR, Ittner LM, Halliday GM.

Brain. 2018 Feb 1;141(2):521-534. doi: 10.1093/brain/awx328.


Labeling and identifying cell-specific proteomes in the mouse brain.

Krogager TP, Ernst RJ, Elliott TS, Calo L, Beránek V, Ciabatti E, Spillantini MG, Tripodi M, Hastings MH, Chin JW.

Nat Biotechnol. 2018 Feb;36(2):156-159. doi: 10.1038/nbt.4056. Epub 2017 Dec 18.


Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions.

Sidoryk-Wegrzynowicz M, Gerber YN, Ries M, Sastre M, Tolkovsky AM, Spillantini MG.

Acta Neuropathol Commun. 2017 Nov 29;5(1):89. doi: 10.1186/s40478-017-0478-9.


Atypical, non-standard functions of the microtubule associated Tau protein.

Sotiropoulos I, Galas MC, Silva JM, Skoulakis E, Wegmann S, Maina MB, Blum D, Sayas CL, Mandelkow EM, Mandelkow E, Spillantini MG, Sousa N, Avila J, Medina M, Mudher A, Buee L.

Acta Neuropathol Commun. 2017 Nov 29;5(1):91. doi: 10.1186/s40478-017-0489-6. Review.


Neurodegeneration and the ordered assembly of α-synuclein.

Spillantini MG, Goedert M.

Cell Tissue Res. 2018 Jul;373(1):137-148. doi: 10.1007/s00441-017-2706-9. Epub 2017 Nov 8. Review.


The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice.

Migdalska-Richards A, Wegrzynowicz M, Rusconi R, Deangeli G, Di Monte DA, Spillantini MG, Schapira AHV.

Brain. 2017 Oct 1;140(10):2706-2721. doi: 10.1093/brain/awx221.


Antibody recognizing 4-sulfated chondroitin sulfate proteoglycans restores memory in tauopathy-induced neurodegeneration.

Yang S, Hilton S, Alves JN, Saksida LM, Bussey T, Matthews RT, Kitagawa H, Spillantini MG, Kwok JCF, Fawcett JW.

Neurobiol Aging. 2017 Nov;59:197-209. doi: 10.1016/j.neurobiolaging.2017.08.002. Epub 2017 Aug 9.


Propagation of Tau aggregates.

Goedert M, Spillantini MG.

Mol Brain. 2017 May 30;10(1):18. doi: 10.1186/s13041-017-0298-7. Review.


The Synucleinopathies: Twenty Years On.

Goedert M, Jakes R, Spillantini MG.

J Parkinsons Dis. 2017;7(s1):S51-S69. doi: 10.3233/JPD-179005. Review.


[18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation.

Bevan Jones WR, Cope TE, Passamonti L, Fryer TD, Hong YT, Aigbirhio F, Kril JJ, Forrest SL, Allinson K, Coles JP, Simon Jones P, Spillantini MG, Hodges JR, O'Brien JT, Rowe JB.

Ann Clin Transl Neurol. 2016 Oct 18;3(12):940-947. doi: 10.1002/acn3.366. eCollection 2016 Dec.


The Transcellular Propagation and Intracellular Trafficking of α-Synuclein.

Tofaris GK, Goedert M, Spillantini MG.

Cold Spring Harb Perspect Med. 2017 Sep 1;7(9). pii: a024380. doi: 10.1101/cshperspect.a024380. Review.


Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy.

Rittman T, Rubinov M, Vértes PE, Patel AX, Ginestet CE, Ghosh BCP, Barker RA, Spillantini MG, Bullmore ET, Rowe JB.

Neurobiol Aging. 2016 Dec;48:153-160. doi: 10.1016/j.neurobiolaging.2016.09.001. Epub 2016 Sep 9.


Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system.

Yang S, Kuan WL, Spillantini MG.

Eur J Neurosci. 2016 Sep;44(6):2396-403. doi: 10.1111/ejn.13333. Epub 2016 Sep 5.


Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy.

Mazzaro N, Barini E, Spillantini MG, Goedert M, Medini P, Gasparini L.

J Neurosci. 2016 Feb 17;36(7):2086-100. doi: 10.1523/JNEUROSCI.0774-15.2016.


Synucleinopathies: past, present and future.

Spillantini MG, Goedert M.

Neuropathol Appl Neurobiol. 2016 Feb;42(1):3-5. doi: 10.1111/nan.12311. No abstract available.


pFTAA: a high affinity oligothiophene probe that detects filamentous tau in vivo and in cultured neurons.

Brelstaff J, Spillantini MG, Tolkovsky AM.

Neural Regen Res. 2015 Nov;10(11):1746-7. doi: 10.4103/1673-5374.165298. No abstract available.


Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation.

Ossola B, Zhao C, Compston A, Pluchino S, Franklin RJ, Spillantini MG.

Glia. 2016 Mar;64(3):457-71. doi: 10.1002/glia.22940. Epub 2015 Nov 18.


Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit.

Tozzi A, de Iure A, Bagetta V, Tantucci M, Durante V, Quiroga-Varela A, Costa C, Di Filippo M, Ghiglieri V, Latagliata EC, Wegrzynowicz M, Decressac M, Giampà C, Dalley JW, Xia J, Gardoni F, Mellone M, El-Agnaf OM, Ardah MT, Puglisi-Allegra S, Björklund A, Spillantini MG, Picconi B, Calabresi P.

Biol Psychiatry. 2016 Mar 1;79(5):402-414. doi: 10.1016/j.biopsych.2015.08.013. Epub 2015 Aug 20.


A Brief History of Tau.

Goedert M, Spillantini MG, Crowther RA.

Clin Chem. 2015 Nov;61(11):1417-8. doi: 10.1373/clinchem.2015.245142. Epub 2015 Sep 1. No abstract available.


Closing the tau loop: the missing tau mutation.

McCarthy A, Lonergan R, Olszewska DA, O'Dowd S, Cummins G, Magennis B, Fallon EM, Pender N, Huey ED, Cosentino S, O'Rourke K, Kelly BD, O'Connell M, Delon I, Farrell M, Spillantini MG, Rowland LP, Fahn S, Craig P, Hutton M, Lynch T.

Brain. 2015 Oct;138(Pt 10):3100-9. doi: 10.1093/brain/awv234. Epub 2015 Aug 21.


Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations.

Iovino M, Agathou S, González-Rueda A, Del Castillo Velasco-Herrera M, Borroni B, Alberici A, Lynch T, O'Dowd S, Geti I, Gaffney D, Vallier L, Paulsen O, Káradóttir RT, Spillantini MG.

Brain. 2015 Nov;138(Pt 11):3345-59. doi: 10.1093/brain/awv222. Epub 2015 Jul 27.


The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice.

Brelstaff J, Ossola B, Neher JJ, Klingstedt T, Nilsson KP, Goedert M, Spillantini MG, Tolkovsky AM.

Front Neurosci. 2015 May 29;9:184. doi: 10.3389/fnins.2015.00184. eCollection 2015.


α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons.

Zaltieri M, Grigoletto J, Longhena F, Navarria L, Favero G, Castrezzati S, Colivicchi MA, Della Corte L, Rezzani R, Pizzi M, Benfenati F, Spillantini MG, Missale C, Spano P, Bellucci A.

J Cell Sci. 2015 Jul 1;128(13):2231-43. doi: 10.1242/jcs.157867. Epub 2015 May 12.


The role of tau in the pathological process and clinical expression of Huntington's disease.

Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J; REGISTRY Investigators of the European Huntington’s Disease Network, Spillantini MG, Cicchetti F, Barker RA.

Brain. 2015 Jul;138(Pt 7):1907-18. doi: 10.1093/brain/awv107. Epub 2015 May 6.


Slowly progressive behavioural presentation in two UK cases with the R406W MAPT mutation.

Wood R, Moodley K, Hodges JR, Allinson K, Spillantini MG, Chan D.

Neuropathol Appl Neurobiol. 2016 Apr;42(3):291-5. doi: 10.1111/nan.12247. Epub 2015 May 30. No abstract available.


Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure.

Navarria L, Zaltieri M, Longhena F, Spillantini MG, Missale C, Spano P, Bellucci A.

Neurochem Int. 2015 Jun-Jul;85-86:14-23. doi: 10.1016/j.neuint.2015.03.008. Epub 2015 Apr 3.


Impaired intracellular trafficking defines early Parkinson's disease.

Hunn BH, Cragg SJ, Bolam JP, Spillantini MG, Wade-Martins R.

Trends Neurosci. 2015 Mar;38(3):178-88. doi: 10.1016/j.tins.2014.12.009. Epub 2015 Jan 29. Review.


PART is part of Alzheimer disease.

Duyckaerts C, Braak H, Brion JP, Buée L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M, Uchihara T.

Acta Neuropathol. 2015 May;129(5):749-56. doi: 10.1007/s00401-015-1390-7. Epub 2015 Jan 28.


Organisation and tyrosine hydroxylase and calretinin immunoreactivity in the main olfactory bulb of paca (Cuniculus paca): a large caviomorph rodent.

Sasahara TH, Leal LM, Spillantini MG, Machado MR.

Neurochem Res. 2015 Apr;40(4):740-6. doi: 10.1007/s11064-015-1522-4. Epub 2015 Jan 28.


Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology.

Yang S, Cacquevel M, Saksida LM, Bussey TJ, Schneider BL, Aebischer P, Melani R, Pizzorusso T, Fawcett JW, Spillantini MG.

Exp Neurol. 2015 Mar;265:48-58. doi: 10.1016/j.expneurol.2014.11.013. Epub 2014 Dec 4.


Parkinson's disease as a member of Prion-like disorders.

Herva ME, Spillantini MG.

Virus Res. 2015 Sep 2;207:38-46. doi: 10.1016/j.virusres.2014.10.016. Epub 2014 Nov 4. Review.


Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein.

Hall K, Yang S, Sauchanka O, Spillantini MG, Anichtchik O.

Exp Neurol. 2015 Feb;264:8-13. doi: 10.1016/j.expneurol.2014.11.003. Epub 2014 Nov 20.


Frontotemporal dementia and its subtypes: a genome-wide association study.

Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, Dobson-Stone C, Brooks WS, Schofield PR, Halliday GM, Hodges JR, Piguet O, Bartley L, Thompson E, Haan E, Hernández I, Ruiz A, Boada M, Borroni B, Padovani A, Cruchaga C, Cairns NJ, Benussi L, Binetti G, Ghidoni R, Forloni G, Galimberti D, Fenoglio C, Serpente M, Scarpini E, Clarimón J, Lleó A, Blesa R, Waldö ML, Nilsson K, Nilsson C, Mackenzie IR, Hsiung GY, Mann DM, Grafman J, Morris CM, Attems J, Griffiths TD, McKeith IG, Thomas AJ, Pietrini P, Huey ED, Wassermann EM, Baborie A, Jaros E, Tierney MC, Pastor P, Razquin C, Ortega-Cubero S, Alonso E, Perneczky R, Diehl-Schmid J, Alexopoulos P, Kurz A, Rainero I, Rubino E, Pinessi L, Rogaeva E, St George-Hyslop P, Rossi G, Tagliavini F, Giaccone G, Rowe JB, Schlachetzki JC, Uphill J, Collinge J, Mead S, Danek A, Van Deerlin VM, Grossman M, Trojanowski JQ, van der Zee J, Deschamps W, Van Langenhove T, Cruts M, Van Broeckhoven C, Cappa SF, Le Ber I, Hannequin D, Golfier V, Vercelletto M, Brice A, Nacmias B, Sorbi S, Bagnoli S, Piaceri I, Nielsen JE, Hjermind LE, Riemenschneider M, Mayhaus M, Ibach B, Gasparoni G, Pichler S, Gu W, Rossor MN, Fox NC, Warren JD, Spillantini MG, Morris HR, Rizzu P, Heutink P, Snowden JS, Rollinson S, Richardson A, Gerhard A, Bruni AC, Maletta R, Frangipane F, Cupidi C, Bernardi L, Anfossi M, Gallo M, Conidi ME, Smirne N, Rademakers R, Baker M, Dickson DW, Graff-Radford NR, Petersen RC, Knopman D, Josephs KA, Boeve BF, Parisi JE, Seeley WW, Miller BL, Karydas AM, Rosen H, van Swieten JC, Dopper EG, Seelaar H, Pijnenburg YA, Scheltens P, Logroscino G, Capozzo R, Novelli V, Puca AA, Franceschi M, Postiglione A, Milan G, Sorrentino P, Kristiansen M, Chiang HH, Graff C, Pasquier F, Rollin A, Deramecourt V, Lebert F, Kapogiannis D, Ferrucci L, Pickering-Brown S, Singleton AB, Hardy J, Momeni P.

Lancet Neurol. 2014 Jul;13(7):686-99. doi: 10.1016/S1474-4422(14)70065-1.


Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA).

Herva ME, Zibaee S, Fraser G, Barker RA, Goedert M, Spillantini MG.

J Biol Chem. 2014 Apr 25;289(17):11897-905. doi: 10.1074/jbc.M113.542340. Epub 2014 Feb 28.


The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons.

Iovino M, Pfisterer U, Holton JL, Lashley T, Swingler RJ, Calo L, Treacy R, Revesz T, Parmar M, Goedert M, Muqit MM, Spillantini MG.

Acta Neuropathol. 2014 Feb;127(2):283-95. doi: 10.1007/s00401-013-1219-1. Epub 2013 Nov 30.


Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies.

Mellone M, Kestoras D, Andrews MR, Dassie E, Crowther RA, Stokin GB, Tinsley J, Horne G, Goedert M, Tolkovsky AM, Spillantini MG.

J Neurosci. 2013 Nov 13;33(46):18175-89. doi: 10.1523/JNEUROSCI.4933-12.2013.


Synaptic dysfunction in synucleinopathies.

Anichtchik O, Calo L, Spillantini MG.

CNS Neurol Disord Drug Targets. 2013 Dec;12(8):1094-100. Review.


Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra.

Garcia-Reitboeck P, Anichtchik O, Dalley JW, Ninkina N, Tofaris GK, Buchman VL, Spillantini MG.

Exp Neurol. 2013 Oct;248:541-5. doi: 10.1016/j.expneurol.2013.07.015. Epub 2013 Aug 8.


Tau pathology and neurodegeneration.

Spillantini MG, Goedert M.

Lancet Neurol. 2013 Jun;12(6):609-22. doi: 10.1016/S1474-4422(13)70090-5. Review.


Depletion of perineuronal nets enhances recognition memory and long-term depression in the perirhinal cortex.

Romberg C, Yang S, Melani R, Andrews MR, Horner AE, Spillantini MG, Bussey TJ, Fawcett JW, Pizzorusso T, Saksida LM.

J Neurosci. 2013 Apr 17;33(16):7057-65. doi: 10.1523/JNEUROSCI.6267-11.2013.


Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model.

Dassie E, Andrews MR, Bensadoun JC, Cacquevel M, Schneider BL, Aebischer P, Wouters FS, Richardson JC, Hussain I, Howlett DR, Spillantini MG, Fawcett JW.

Neurobiol Aging. 2013 May;34(5):1355-68. doi: 10.1016/j.neurobiolaging.2012.11.011. Epub 2012 Dec 25.


100 years of Lewy pathology.

Goedert M, Spillantini MG, Del Tredici K, Braak H.

Nat Rev Neurol. 2013 Jan;9(1):13-24. doi: 10.1038/nrneurol.2012.242. Epub 2012 Nov 27. Review.


Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant.

King A, Al-Sarraj S, Troakes C, Smith BN, Maekawa S, Iovino M, Spillantini MG, Shaw CE.

Acta Neuropathol. 2013 Feb;125(2):303-10. doi: 10.1007/s00401-012-1050-0. Epub 2012 Sep 28.


Late-onset Parkinsonism in NFκB/c-Rel-deficient mice.

Baiguera C, Alghisi M, Pinna A, Bellucci A, De Luca MA, Frau L, Morelli M, Ingrassia R, Benarese M, Porrini V, Pellitteri M, Bertini G, Fabene PF, Sigala S, Spillantini MG, Liou HC, Spano PF, Pizzi M.

Brain. 2012 Sep;135(Pt 9):2750-65. doi: 10.1093/brain/aws193. Epub 2012 Aug 21.


Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.

Bezard E, Yue Z, Kirik D, Spillantini MG.

Mov Disord. 2013 Jan;28(1):61-70. doi: 10.1002/mds.25108. Epub 2012 Jul 2. Review.


Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.

Costa C, Sgobio C, Siliquini S, Tozzi A, Tantucci M, Ghiglieri V, Di Filippo M, Pendolino V, de Iure A, Marti M, Morari M, Spillantini MG, Latagliata EC, Pascucci T, Puglisi-Allegra S, Gardoni F, Di Luca M, Picconi B, Calabresi P.

Brain. 2012 Jun;135(Pt 6):1884-99. doi: 10.1093/brain/aws101. Epub 2012 May 4.


Reduced axonal transport and increased excitotoxic retinal ganglion cell degeneration in mice transgenic for human mutant P301S tau.

Bull ND, Guidi A, Goedert M, Martin KR, Spillantini MG.

PLoS One. 2012;7(4):e34724. doi: 10.1371/journal.pone.0034724. Epub 2012 Apr 4.

Supplemental Content

Loading ...
Support Center